Cover Image
市場調查報告書

D型肝炎:開發中產品分析

Hepatitis D - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245993
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
D型肝炎:開發中產品分析 Hepatitis D - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 71 Pages
簡介

所謂D型肝炎是受到D型肝炎病毒(HDV,三角洲病毒)感染,使肝臟腫起這樣的感染疾病。主要症狀有皮膚·眼球的黃疸和關節痛·腹痛,噁心,食慾不振,倦怠感等。主要風險要素包含大量輸血,及靜脈注射(IV)藥物·注射藥的濫用,妊娠中的感染等。

本報告提供全球各國治療D型肝炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

D型肝炎概要

治療藥的開發

  • D型肝炎開發中產品:概要
  • 各企業治療藥
  • 各大學/研究機關的治療藥
  • 開發中的產品一覽(各企業)
  • 開發中的產品一覽(各大學/研究機關)

D型肝炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各分子類型

D型肝炎開發治療藥的企業

  • Alnylam Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • Spring Bank Pharmaceuticals Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9254IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H1 2017, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis D - Overview
    • Hepatitis D - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
    • Hepatitis D - Therapeutics Assessment
  • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis D - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Eiger BioPharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Globeimmune Inc
    • Replicor Inc
    • Rodos BioTarget GmbH
    • SomaGenics Inc
    • Spring Bank Pharmaceuticals Inc
  • Hepatitis D - Drug Profiles
    • ALN-HDV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GI-18000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lonafarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myrcludex-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon lambda-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBT-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Oligonucleotide for Hepatitis D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-9200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vanitaracin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis D - Dormant Projects
  • Hepatitis D - Discontinued Products
  • Hepatitis D - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling
      • Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017
      • Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
      • Apr 04, 2017: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
      • Feb 20, 2017: Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017
      • Nov 15, 2016: Replicor Discloses Late Breaking HBV and Follow-Up HBV / HDV Clinical Data at AASLD 2016
      • Nov 14, 2016: Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting
      • Oct 19, 2016: Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus Infection
      • Oct 13, 2016: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
      • Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
      • Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV - 3 Study at National Institutes of Health
      • Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
      • May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
      • Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B
      • Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis D, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hepatitis D - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
  • Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H1 2017
  • Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Hepatitis D - Pipeline by Globeimmune Inc, H1 2017
  • Hepatitis D - Pipeline by Replicor Inc, H1 2017
  • Hepatitis D - Pipeline by Rodos BioTarget GmbH, H1 2017
  • Hepatitis D - Pipeline by SomaGenics Inc, H1 2017
  • Hepatitis D - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
  • Hepatitis D - Dormant Projects, H1 2017
  • Hepatitis D - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hepatitis D, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top